1988, Dai 1-han., 7, 9, 256
Book
2010, ISBN 9784819111102, 230
Book
2007, Shohan., JIPAS kenkyū shirīzu, ISBN 9784902962062, Volume 2, 126
Book
Kaibogaku zasshi. Journal of anatomy, ISSN 0022-7722, 06/2014, Volume 89, Issue 3, p. 15
Journal Article
Kaibogaku zasshi. Journal of anatomy, ISSN 0022-7722, 2014, Volume 89, Issue 3, pp. 15 - 16
Journal Article
1989, ISBN 4377308114, 6, 232
Book
1981, ix, 204
Book
1985, Shohan., 168
Book
World Neurosurgery, ISSN 1878-8750, 10/2019, Volume 130, pp. e26 - e46
The epidemiology of patients with traumatic brain injury (TBI) has changed dramatically over recent decades as a result of rapid advances in aging societies....
Aging | Hospital mortality | Prognosis | Traumatic brain injury | Subdural hematoma | SURGERY | CARE | CLINICAL NEUROLOGY | IMPACT | CLINICAL-VARIABLES | HOSPITAL VOLUME | GENDER | COMA
Aging | Hospital mortality | Prognosis | Traumatic brain injury | Subdural hematoma | SURGERY | CARE | CLINICAL NEUROLOGY | IMPACT | CLINICAL-VARIABLES | HOSPITAL VOLUME | GENDER | COMA
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 1, pp. e23 - e31
Summary Lung cancer is the leading cause of cancer-related death. The identification of epidermal growth factor receptor (EGFR) somatic mutations defined a...
Hematology, Oncology and Palliative Medicine | GENE-MUTATIONS | PHASE-II TRIAL | GEFITINIB | DOMAIN | RESPONSIVENESS | GROWTH-FACTOR-RECEPTOR | ONCOLOGY | INCREASED SENSITIVITY | RESISTANCE | TYROSINE KINASE INHIBITOR | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Exons | Humans | Lung Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Structure-Activity Relationship | Molecular Targeted Therapy | Protein Kinase Inhibitors - chemistry | Receptor, Epidermal Growth Factor - metabolism | Drug Design | Precision Medicine | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Genetic Predisposition to Disease | Lung Neoplasms - enzymology | Carcinoma, Non-Small-Cell Lung - genetics | Models, Molecular | Antineoplastic Agents - chemistry | Receptor, Epidermal Growth Factor - chemistry | Drug Resistance, Neoplasm - genetics | Phenotype | Animals | Protein Kinase Inhibitors - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Protein Conformation | Biomarkers, Tumor - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Tyrosine | Genetic aspects | Product development | Epidermal growth factor | Lung cancer, Non-small cell
Hematology, Oncology and Palliative Medicine | GENE-MUTATIONS | PHASE-II TRIAL | GEFITINIB | DOMAIN | RESPONSIVENESS | GROWTH-FACTOR-RECEPTOR | ONCOLOGY | INCREASED SENSITIVITY | RESISTANCE | TYROSINE KINASE INHIBITOR | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Exons | Humans | Lung Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Structure-Activity Relationship | Molecular Targeted Therapy | Protein Kinase Inhibitors - chemistry | Receptor, Epidermal Growth Factor - metabolism | Drug Design | Precision Medicine | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Genetic Predisposition to Disease | Lung Neoplasms - enzymology | Carcinoma, Non-Small-Cell Lung - genetics | Models, Molecular | Antineoplastic Agents - chemistry | Receptor, Epidermal Growth Factor - chemistry | Drug Resistance, Neoplasm - genetics | Phenotype | Animals | Protein Kinase Inhibitors - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Protein Conformation | Biomarkers, Tumor - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Tyrosine | Genetic aspects | Product development | Epidermal growth factor | Lung cancer, Non-small cell
Journal Article
1981, ix, 201
Book
International Journal of Clinical Oncology, ISSN 1341-9625, 12/2018, Volume 23, Issue 6, pp. 1148 - 1159
Investigating oncological outcomes in patients registered in the Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS) in...
External beam radiation therapy | Iodine-125 | Medicine & Public Health | Oncology | Cancer Research | Brachytherapy | Surgical Oncology | Prostate cancer | ANDROGEN SUPPRESSION | DEFINITION | BIOCHEMICAL FAILURE | ANTIGEN BOUNCE | RADIATION | ONCOLOGY | PSA KINETICS | MEN | RECTAL MORBIDITY | RADIOTHERAPY | Prostate-Specific Antigen | Multivariate Analysis | Prostatic Neoplasms - pathology | Prostatic Neoplasms - radiotherapy | Follow-Up Studies | Humans | Japan | Middle Aged | Risk Factors | Brachytherapy - methods | Male | Treatment Outcome | Prostatic Neoplasms - mortality | Iodine Radioisotopes - therapeutic use | Survival Analysis | Aged | Research | Oncology, Experimental | Analysis | Patient outcomes | Cancer
External beam radiation therapy | Iodine-125 | Medicine & Public Health | Oncology | Cancer Research | Brachytherapy | Surgical Oncology | Prostate cancer | ANDROGEN SUPPRESSION | DEFINITION | BIOCHEMICAL FAILURE | ANTIGEN BOUNCE | RADIATION | ONCOLOGY | PSA KINETICS | MEN | RECTAL MORBIDITY | RADIOTHERAPY | Prostate-Specific Antigen | Multivariate Analysis | Prostatic Neoplasms - pathology | Prostatic Neoplasms - radiotherapy | Follow-Up Studies | Humans | Japan | Middle Aged | Risk Factors | Brachytherapy - methods | Male | Treatment Outcome | Prostatic Neoplasms - mortality | Iodine Radioisotopes - therapeutic use | Survival Analysis | Aged | Research | Oncology, Experimental | Analysis | Patient outcomes | Cancer
Journal Article
Molecules, ISSN 1420-3049, 2018, Volume 23, Issue 8, p. 1938
The CCAAT enhancer-binding protein alpha (C/EBP alpha) plays an important role in myeloid cell differentiation and in the enhancement of C/EBP alpha...
Myeloid differentiation | CCAAT/enhancer binding protein α | THERAPY | BIOCHEMISTRY & MOLECULAR BIOLOGY | TUBULIN POLYMERIZATION | myeloid differentiation | AGENTS | LEUKEMIA | CCAAT/enhancer binding protein alpha | CYTOTOXICITY | CANCER | CHEMISTRY, MULTIDISCIPLINARY | Up-Regulation | CCAAT-Enhancer-Binding Protein-alpha - metabolism | Apoptosis - drug effects | Leukemia, Myeloid, Acute - pathology | Humans | Leukemia, Myeloid, Acute - metabolism | Transcriptional Activation | Structure-Activity Relationship | Small Molecule Libraries - chemistry | Styrenes - pharmacology | Granulocytes - drug effects | Cell Differentiation - drug effects | Hematopoiesis | HL-60 Cells | Granulocytes - pathology | CD11b Antigen - metabolism | Quinazolinones - pharmacology | Proteins | Quinazolinones | CD11b antigen | Myeloid leukemia | Leukemia | Differentiation (biology) | Cell lines | Tumor cell lines | CCAAT/enhancer-binding protein | Cell differentiation | Acute myeloid leukemia | Inducers
Myeloid differentiation | CCAAT/enhancer binding protein α | THERAPY | BIOCHEMISTRY & MOLECULAR BIOLOGY | TUBULIN POLYMERIZATION | myeloid differentiation | AGENTS | LEUKEMIA | CCAAT/enhancer binding protein alpha | CYTOTOXICITY | CANCER | CHEMISTRY, MULTIDISCIPLINARY | Up-Regulation | CCAAT-Enhancer-Binding Protein-alpha - metabolism | Apoptosis - drug effects | Leukemia, Myeloid, Acute - pathology | Humans | Leukemia, Myeloid, Acute - metabolism | Transcriptional Activation | Structure-Activity Relationship | Small Molecule Libraries - chemistry | Styrenes - pharmacology | Granulocytes - drug effects | Cell Differentiation - drug effects | Hematopoiesis | HL-60 Cells | Granulocytes - pathology | CD11b Antigen - metabolism | Quinazolinones - pharmacology | Proteins | Quinazolinones | CD11b antigen | Myeloid leukemia | Leukemia | Differentiation (biology) | Cell lines | Tumor cell lines | CCAAT/enhancer-binding protein | Cell differentiation | Acute myeloid leukemia | Inducers
Journal Article
1987, Shohan., vi, 692
Book
Biological and Pharmaceutical Bulletin, ISSN 0918-6158, 2018, Volume 41, Issue 3, pp. 374 - 382
Bisphenol A (BPA, 2,2-bis(4-hydroxyphenyl)propane), one of the phenolic compounds widely used in the manufacture of plastic and epoxy resins, is known as an...
hypoxia inducible factor-1alpha | Bisphenol A | hypoxia response | Hypoxia response | Hypoxia inducible factor-1alpha | ACTIVATION | MECHANISM | TRANSCRIPTION | HYPOXIA | ESTROGEN-RECEPTOR | MASS-SPECTROMETRY | PREGNANE X RECEPTOR | LIVER | PHARMACOLOGY & PHARMACY | HIF-1-ALPHA | EXPOSURE | Hypoxia-Inducible Factor 1, alpha Subunit - drug effects | Lysosomes - drug effects | HSC70 Heat-Shock Proteins - genetics | Humans | RNA, Small Interfering - pharmacology | Air Pollutants, Occupational - pharmacology | Benzhydryl Compounds - chemistry | Liver Neoplasms, Experimental - metabolism | Animals | HSC70 Heat-Shock Proteins - biosynthesis | Signal Transduction - drug effects | Cell Line, Tumor | Phenols - chemistry | Benzhydryl Compounds - pharmacology | Phenols - pharmacology | Hsp90 protein | Ammonium | Heat shock proteins | Lysosomes | Derivatives | Phenolic compounds | Ammonium chlorides | Proteasome inhibitors | Degradation | Ammonium chloride | Proteins | Hypoxia-inducible factor 1a | Inhibitors | Enzyme inhibitors | Epoxy resins | Cyclohexane | Phenols | Proteasomes | Hypoxia | Hsc70 protein | Heat shock
hypoxia inducible factor-1alpha | Bisphenol A | hypoxia response | Hypoxia response | Hypoxia inducible factor-1alpha | ACTIVATION | MECHANISM | TRANSCRIPTION | HYPOXIA | ESTROGEN-RECEPTOR | MASS-SPECTROMETRY | PREGNANE X RECEPTOR | LIVER | PHARMACOLOGY & PHARMACY | HIF-1-ALPHA | EXPOSURE | Hypoxia-Inducible Factor 1, alpha Subunit - drug effects | Lysosomes - drug effects | HSC70 Heat-Shock Proteins - genetics | Humans | RNA, Small Interfering - pharmacology | Air Pollutants, Occupational - pharmacology | Benzhydryl Compounds - chemistry | Liver Neoplasms, Experimental - metabolism | Animals | HSC70 Heat-Shock Proteins - biosynthesis | Signal Transduction - drug effects | Cell Line, Tumor | Phenols - chemistry | Benzhydryl Compounds - pharmacology | Phenols - pharmacology | Hsp90 protein | Ammonium | Heat shock proteins | Lysosomes | Derivatives | Phenolic compounds | Ammonium chlorides | Proteasome inhibitors | Degradation | Ammonium chloride | Proteins | Hypoxia-inducible factor 1a | Inhibitors | Enzyme inhibitors | Epoxy resins | Cyclohexane | Phenols | Proteasomes | Hypoxia | Hsc70 protein | Heat shock
Journal Article
International Journal of Hematology, ISSN 0925-5710, 1/2019, Volume 109, Issue 1, pp. 28 - 34
Transcription factors recognize and bind to consensus sequence elements that are specific for each transcription factor, and the transcription factors then...
Medicine & Public Health | Hematology | Granulocyte | Oncology | Transcription factor | Differentiation | Acute myeloid leukemia | FACTOR-C/EBP-ALPHA | C-MYC | BINDING PROTEIN | PU.1 | GALIELLALACTONE | INHIBITORS | MUTATIONS | INDUCER | HEMATOLOGY | EXPRESSION | ERYTHROID-DIFFERENTIATION | Carcinogenesis - drug effects | Leukemia, Myeloid, Acute - drug therapy | Humans | Molecular Targeted Therapy - methods | Leukemia, Myeloid, Acute - genetics | Transcription Factors - drug effects | Transcription factors | Myeloid leukemia | Leukemia | Gene regulation | Runx1 protein | Gene expression | Hemopoiesis | Conserved sequence | PU.1 protein | Bone marrow | Leukemogenesis | Hematopoietic system | Mutation | Chromosome aberrations | Cancer | Tumors
Medicine & Public Health | Hematology | Granulocyte | Oncology | Transcription factor | Differentiation | Acute myeloid leukemia | FACTOR-C/EBP-ALPHA | C-MYC | BINDING PROTEIN | PU.1 | GALIELLALACTONE | INHIBITORS | MUTATIONS | INDUCER | HEMATOLOGY | EXPRESSION | ERYTHROID-DIFFERENTIATION | Carcinogenesis - drug effects | Leukemia, Myeloid, Acute - drug therapy | Humans | Molecular Targeted Therapy - methods | Leukemia, Myeloid, Acute - genetics | Transcription Factors - drug effects | Transcription factors | Myeloid leukemia | Leukemia | Gene regulation | Runx1 protein | Gene expression | Hemopoiesis | Conserved sequence | PU.1 protein | Bone marrow | Leukemogenesis | Hematopoietic system | Mutation | Chromosome aberrations | Cancer | Tumors
Journal Article
2005, ISBN 9784794213815, 257
Book
Angewandte Chemie International Edition, ISSN 1433-7851, 02/2016, Volume 55, Issue 8, pp. 2697 - 2700
Direct use of low pressures of CO2 as a C1 source without concentration from gas mixtures is of great interest from an energy‐saving viewpoint. Porous...
ruthenium | metal–organic frameworks | photocatalysis | microporous materials | carbon dioxide fixation | metal-organic frameworks | STABILITY | ADSORPTION | CHEMISTRY, MULTIDISCIPLINARY | FUNCTIONALIZATION | VISIBLE-LIGHT | ROBUST | ASSISTED LINKER EXCHANGE | CARBON-DIOXIDE REDUCTION | CAPTURE | CATALYSTS | Ruthenium | Adsorption | Energy conservation | Chemical properties | Polymer industry | Catalysis | Polymers | Catalysts | Low concentrations | Carbon dioxide | Catalytic activity | Gas mixtures | Ruthenium compounds | Reduction | Composite materials | Ambient temperature | Temperature effects | Synergistic effect | Carbon monoxide
ruthenium | metal–organic frameworks | photocatalysis | microporous materials | carbon dioxide fixation | metal-organic frameworks | STABILITY | ADSORPTION | CHEMISTRY, MULTIDISCIPLINARY | FUNCTIONALIZATION | VISIBLE-LIGHT | ROBUST | ASSISTED LINKER EXCHANGE | CARBON-DIOXIDE REDUCTION | CAPTURE | CATALYSTS | Ruthenium | Adsorption | Energy conservation | Chemical properties | Polymer industry | Catalysis | Polymers | Catalysts | Low concentrations | Carbon dioxide | Catalytic activity | Gas mixtures | Ruthenium compounds | Reduction | Composite materials | Ambient temperature | Temperature effects | Synergistic effect | Carbon monoxide
Journal Article
No results were found for your search.
Cannot display more than 1000 results, please narrow the terms of your search.